Urothelial cancer (bladder and urinary tract) New evidence of the value of immunotherapy
Urothelial cancer, usually developing in the bladder, is common and serious. Its management is complex. It accounts for 90% of bladder cancers. With 12,000 new cases diagnosed each year in France, bladder cancer is the urological cancer encountered most frequently after prostate cancer.
As every year for almost 55 years, the world’s leading cancer experts will meet in Chicago to talk about the latest advances in clinical oncology at the international meeting of the American Society of Clinical Oncology (ASCO). Naturally, Gustave Roussy will be one of the best represented institutions at this conference.
As every year, the world’s leading cancer experts meet in Chicago to talk about the latest advances in clinical oncology at the international meeting of the American Society of Clinical Oncology (ASCO). Naturally, Gustave Roussy is one of the best represented institutions at this conference.
Une Recherche Hospitalo-Universitaire pour étudier le rôle du microbiote intestinal dans la réponse aux immunothérapies anticancéreuses dans les cancers bronchiques.